A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ProVent
- Sponsors Dendreon Corporation
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 25 Sep 2018 Status changed from planning to not yet recruiting.
- 25 May 2018 New trial record